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Background and purpose — Patients undergoing total knee 
arthroplasty (TKA) face challenges related to postoperative 
reduction in knee-extension strength. We evaluated whether inhi-
bition of the inflammatory response by a single preoperative dose 
of methylprednisolone (MP) reduces the pronounced loss of knee-
extension strength at discharge after fast-track TKA.
Patients and methods — 70 patients undergoing elective uni-
lateral TKA were randomized (1:1) to preoperative intravenous 
(IV) MP 125 mg (group MP) or isotonic saline IV (group C). All 
procedures were performed under spinal anesthesia without tour-
niquet, and with a standardized multimodal analgesic regime. 
The primary outcome was change in knee-extension strength 
from baseline to 48 hours postoperatively. Secondary outcomes 
were knee joint circumference, functional performance using the 
Timed Up and Go (TUG) test, pain during the aforementioned 
tests, rescue analgesic requirements, and plasma C-reactive pro-
tein (CRP) changes.
Results — 61 patients completed the follow-up. The loss in 
quadriceps muscle strength was similar between groups; group 
MP 1.04 (0.22–1.91) Nm/kg (–89%) vs. group C 1.02 (0.22–1.57) 
Nm/kg (–88%). Also between-group differences were similar for 
knee circumference, TUG test, and pain scores. MP reduced the 
inflammatory response (CRP) at 24 hours postoperatively; group 
MP 33 (IQR 21–50) mg/L vs. group C 72 (IQR 58–92) mg/L (p < 
0.001), and 48 hours postoperatively; group MP 83 (IQR 56–125) 
mg/L vs. group C 192 (IQR 147–265) mg/L (p < 0.001), respec-
tively. 
Interpretation — Preoperative systemic administration of MP 
125 mg did not reduce the pronounced loss of knee-extension 
strength or other functional outcomes at discharge after fast-
track TKA despite a reduced systemic inflammatory response. 

Patients undergoing total knee arthroplasty (TKA) face chal-
lenges related to postoperative pain and decreased functional 
performance, the latter related to the reduction in knee-exten-
sion strength. Thus, the profound reduction by about 80% in 
early postoperative in knee-extension strength after TKA is 
well known (Holm et al. 2010, Mizner et al. 2005b) and lim-
ited strength may contribute to delayed early mobilization and 
hospital discharge, as well as risk of falling (de Zwart et al. 
2015). The mechanisms underlying the inhibition of the quad-
riceps muscle after TKA have not been completely clarified, 
but include pain, swelling (Holm et al. 2010), and arthrogenic 
muscle inhibition (Mizner et al. 2005b, Rice and McNair 
2010, Rice et al. 2014). Avoidance of tourniquet use does not 
prevent early loss of knee-extension strength (Harsten et al. 
2015). However, the effect of modulating the inflammatory 
response has not been studied before.
Glucocorticoids are known to reduce the systemic inflam-
matory response after surgery (Smith et al. 2006, Jules-Elysee 
et al. 2012, Jorgensen and Kehlet 2013, Kardash et al. 2008), 
and have well-documented anti-inflammatory effects in gen-
eral (Rhen and Cidlowski 2005) as well as improving pain 
control and early fatigue in total arthroplasty settings (Lunn et 
al. 2011, Backes et al. 2013, Rytter et al. 2017). Furthermore, 
the literature suggests that higher doses of glucocorticoids 
improve pain control and recovery compared with lower doses 
for postoperative nausea and vomiting (PONV) prophylaxis 
(De Oliveira et al. 2011). Since regain of muscle strength is 
important, further studies of the involved pathogenic mecha-
nisms are required (Kehlet 2013). 
To our knowledge, the effect of high-dose glucocorticoid 
administration on knee-extension strength after TKA has not 
been studied. Consequently, the purpose of our study was to 
evaluate whether inhibition of the inflammatory response by 
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a single preoperative high dose of methylprednisolone (MP) 
(Lunn et al. 2011) reduced the loss of knee-extension strength 
at discharge after fast-track TKA. 
Patients and methods
The study was performed as a single-center, randomized, 
placebo-controlled superiority trial with 2 parallel groups, 
and blinding of the participants, intervention deliverers, and 
outcome assessors. Functional outcomes were assessed preop-
eratively (baseline) and 48 hours after surgery. Blood samples 
were collected at baseline, and 2, 6, 24 and 48 hours postop-
eratively. 
Participants
From February 2015 to April 2016, 163 patients undergoing 
elective, unilateral, primary TKA at Copenhagen Univer-
sity Hospital, Bispebjerg and Frederiksberg, Denmark, were 
consecutively assessed for eligibility. The inclusion criteria 
were: ability to speak and understand Danish, and to provide 
informed oral and written consent. The exclusion criteria 
were; age < 55 and > 80 years, general anesthesia, allergy to 
glucocorticoids, daily use of systemic glucocorticoids, local or 
systemic infection, insulin-dependent diabetes mellitus, treat-
ment of peptic ulcer within 30 days from inclusion, cancer, 
autoimmune disease including rheumatoid arthritis, fertile 
women. Patients were enrolled at their pre-surgical hospital 
visit several days prior to their TKA. Randomization was per-
formed after the baseline assessment. Screening for eligibility, 
enrolment, and allocation of patients was carried out by the 
principal investigator.
Randomization, trial intervention, and blinding
70 included patients were randomly allocated to 2 groups of 
35 (Figure 1). A research assistant not otherwise involved in 
the trial performed a computer-generated random allocation 
sequence (1:1 allocation rate) concealed in 70 consecutively 
numbered, opaque, sealed envelopes determining active treat-
ment or placebo. On the morning of surgery the envelopes 
were opened consecutively, and the trial drug was prepared 
by 2 anesthetist nurses not otherwise involved in the collec-
tion of trial data. The patients received either a single dose of 
MP, 125 mg (2 mL) IV (Solu-Medrol®; Pfizer, Ballerup, Den-
mark) (group MP) or a single dose of isotonic saline (2 mL) 
IV (group C). Even though both solutions were transparent 
and identical in appearance, the syringes were masked. The 
principal investigator administered the test solution immedi-
ately after spinal anesthesia. Trial participants, care provid-
ers, data collectors, and investigators were all blinded to the 
allocation. The blinded randomization list was dispatched to 
the primary investigator only after study termination, enabling 
blinded analyses. After all statistical analyses had been carried 
out the list was un-blinded with respect to intervention type.
Anesthesia and surgery
Standard procedures for anesthesia, surgery, and analgesia 
were followed. Patients received oral paracetamol 1 g and 
naproxen 500 mg about 1 hour prior to surgery. Surgery was 
performed under lumbar spinal anesthesia with 7.5–12.5 
mg hyperbaric bupivacaine (5 mg/mL, 0.5%) and sedation 
with propofol (1–5 mg/kg/h) was administered as required. 
Immediately after spinal anesthesia cefuroxime 1.5 g and 
tranexamic acid 1 g were administered IV. Intraoperative fluid 
therapy was standardized and consisted of 0.9% saline 12 mL/
kg/h during the first hour of surgery, followed by 6 mL/kg/h if 
the surgery was prolonged beyond 1 hour. 
TKA was performed without the use of a tourniquet or 
drains, and with insertion of tricompartmental prostheses 
(Sigma Total Knee System, DePuy Synthes) via a standard 
medial parapatellar approach. Intraoperatively, local infiltra-
tion of analgesia was performed with 150 mL ropivacaine 
0.2% injected by a systematic technique ensuring uniform 
delivery of local anesthetic to all tissues incised and instru-
mented during the surgery. All procedures were performed by 
3 experienced surgeons specialized in knee arthroplasty sur-
gery. Duration of surgery (minutes) was registered beginning 
with the first incision and ending at the last suture. Ice pack-
ings or mechanical calf compression devices were not used. 
Thrombo-embolic prophylaxis was started 6–8 hours after 
surgery with rivaroxaban 10 mg/day. 
Patients followed a routine, well-defined, fast-track reha-
bilitation regime (Jorgensen and Kehlet 2013) receiving oral 
paracetamol 1 g 4 times daily and naproxen 500 mg twice 
daily from the day of surgery. Rescue analgesia on request 
consisted of opioids (not PCA) if pain exceeded numeric 
rating scale (0–10) at 3 during rest or 5 during active move-
ment. All patients received zolpidem 10 mg at night time and 
postoperative nausea and vomiting (PONV) was treated with 
ondansetron 4 mg. 
Outcome measures
The primary outcome was the change in knee-extension strength 
(Nm/kg body mass) from baseline to discharge. Secondary out-
comes measures included knee joint circumference, Timed Up 
and Go (TUG) test, plasma CRP, and pain assessment during 
the functional tests using visual analogue scale (VAS).
Knee-extension strength
After warm-up and instruction in the procedure, maximal 
isometric knee-extension force was measured using a Good 
Strength adjustable chair (Metitur Ltd, Jyväskylä, Finland) 
using the inherent Metitur software. The chair was adjusted for 
each patient using the same settings pre- and postoperatively 
ensuring an identical individualized setup; hip angle of 90°and 
knee angle of 60° (0° = full extension). The force transducer 
was attached with its center 5 cm proximal to the lateral malle-
olus to measure knee-extension force. Patients were instructed 
to extend “as forcefully as possible with a gradual increase in 
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force”, and strong verbal encouragement was provided during 
contractions. They performed 1 practice trial followed by 5 
contractions separated by 60-second breaks, and the high-
est value was used as result. Knee-extension strength was 
expressed at the maximal voluntary torque per kilo of body 
mass using the external lever-arm length and body mass of 
each patient. Changes of knee-extension strength were quan-
tified as absolute (Nm/kg body mass, primary outcome) and 
relative (%) from preoperative values.
Knee circumference
The knee circumference was measured 1 cm proximal to 
the proximal pole of patella using the same tape measure in 
all patients (Holm et al. 2010) and with the patient relaxed 
in supine position. 2 measurements were performed using 
the highest value as result. Intra-tester reliability has been 
reported to be high, with an intra-class correlation coefficient 
(ICC2,1) of 0.98 (Jakobsen et al. 2010). Knee circumference 
measurements were performed before testing of knee-exten-
sion strength and performance of TUG test to avoid potential 
test-induced supplementary swelling. Changes in knee joint 
circumference were quantified as absolute (centimeters) and 
relative (%) from preoperative values.
Functional performance
The TUG test was used to measure the time (in seconds) it 
took the patients to rise from a chair (chair seat height 0.45 m), 
walk 3m to a line drawn on the floor, and return to the chair as 
quickly and safely as possible. Time was measured from the 
seated position with the back against the backrest with a stop-
watch started on the command “ready–go” and stopped when 
the seated position was regained. Patients performed 3 timed 
trials without prior practice trial (Kristensen et al. 2010). The 
lowest value was used as result. No personal assistance was 
allowed, but verbal guidance was provided, if necessary. No 
walking aid was used at preoperative testing, and 2 elbow 
crutches were used postoperatively.
Knee pain, VAS
Knee pain was quantified using VAS during each active 
assessment. Patients rated pain in and around the operated 
knee immediately after all measurements using a VAS ruler 
on a scale from 0 to 100 mm, with 0 representing no pain 
and 100 representing the worst pain imaginable. We quantified 
changes in pain as absolute (millimeters). 
A single experienced physiotherapist supervised and 
recorded all measurements. Preoperative testing was per-
formed 7–10 days prior to surgery. After preoperative mea-
sures were recorded, preoperative results were not accessible 
until after postoperative measurements had been recorded, in 
an attempt to avoid recall bias.
Paraclinical markers
Blood was drawn at baseline, 2 hours, 6 hours, 24 hours and 
48 hours postoperatively for plasma C-reactive protein (CRP) 
measurements. 
Sample size
The sample size was calculated and estimated for the primary 
outcome assuming a minimal relevant group difference in knee 
extension strength loss of 40% from baseline to 48 hours post-
operatively (40% less loss with MP), corresponding to 0.32 
Nm/kg body weight. The magnitude of this between-group 
difference is larger than that considered the minimal clinically 
important difference, as the average knee-extension strength 
loss at discharge is about 80% (Holm et al. 2010, Mizner et al. 
2005b). In the case of promising results with the use of MP in 
our study, we considered it necessary to verify this in at least 
1 (phase-3-like) confirmatory trial (Christensen and Langberg 
2012). We assumed a 5% significance level, a power of 80%, 
and a common standard deviation (SD) of 0.39 Nm/kg body-
weight (Holm et al. 2010). These calculations resulted in a 
sample size of 52 patients and allowing for 25% drop-outs, 70 
patients were included in the trial.
Statistics
Before analyses, all data were validated by double entry, and 
evaluated for normal distribution by histograms and Q–Q 
plots, and by the Kolmogorov–Smirnov test. All continuous 
variables were compared between allocation groups using 
independent-sample t-tests for normally distributed data or the 
Mann–Whitney U-test for variables not following normal dis-
tribution. Continuous variables are presented as mean (range) 
or median with interquartile range (IQR) as appropriate, and 
categorical variables as number and frequencies (%), respec-
tively. Primary analysis was performed on the per-protocol 
population, and not on the intention-to-treat population as 
stated in the protocol as the excluded patients (due to con-
version to general anesthesia) did not perform postoperative 
functional testing. The planned multiple imputations on drop-
outs for functional outcomes (2 patients) were not performed 
after consultation with a statistician.
Statistical analyses were carried out in SPSS version 22.0 
(IBM Corp., Troy, NY, USA). A 2-sided p-value < 0.05 was 
considered statistically significant.
Ethics, registration, funding and potential conflicts of 
interest
The trial was conducted according to the International Confer-
ence on Harmonization guidelines for Good Clinical Practice 
(GCP) and the principles of the Helsinki Declaration. Before 
patient enrolment, the trial was approved by the Ethics Com-
mittee for the Capital Region of Denmark (H-6-2014-101), 
the Danish Data Protection Agency, the Danish Health and 
Medicine Authority (EudraCT 2014-003395-23), and was reg-
istered on ClinicalTrials.gov under the U.S. National Library 
of Medicine (NCT02319343, https://clinicaltrials.gov/ct2/
show/NCT02319343). The study was monitored by the GCP 
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unit of Copenhagen University Hospital, Copenhagen, Den-
mark. Oral and written informed consent was obtained from 
all patients before participation and the CONSORT recom-
mendations for reporting randomized, controlled, clinical 
trials were followed (Moher et al. 2010).
The work received financial support from the Lundbeck 
Foundation.
No benefits in any form have been received from a com-
mercial party related directly or indirectly to the subject of this 
article. No competing interests declared.
Results
Participants
163 patients were assessed for eligibility. Of these, 93 were 
not eligible or did not consent, leaving 70 patients for ran-
domization (Figure 1). 9 patients were excluded following 
randomization; 5 before receiving the trial drug due to planned 
conversion to general anesthesia, and 2 after receiving the trial 
drug but changed to general anesthesia due to insufficient 
spinal anesthesia. 2 patients (group C) dropped out prior to 
postoperative testing; 1 received a saphenous nerve block in 
the ward because of severe pain, and 1 was subject to postop-
erative flexion restrictions due to risk of joint capsule rupture. 
Consequently, 33 (group MP) and 28 (group C) patients were 
available for analysis of the primary outcome using the non-
missing scores only. Baseline characteristics were comparable 
between allocation groups (Table 1). Likewise, there were no 
between-group differences in intraoperative data including 
versus 72 mg/L, and respectively, 83 mg/L versus 192 mg/L 
48 hours after surgery (p < 0.001). There was no correlation 
between the inflammatory response (CRP) and quadriceps 
muscle strength decline in either group MP (r = –0.20; p = 
0.3) or group C (r = 0.03; p = 0.9).
At the postoperative assessment, 2 patients (1 in each group) 
declined to perform the TUG because of fatigue and nausea. 
Median length of stay (LOS) in both groups was 2 (IQR 2–2) 
days.
There were no wound complications, deep infections, 
or clinically apparent VTE in either group during the study 
period.
Assessed for eligibility
n = 163
Randomized
n = 70
Allocated to methylprednisolone 
125 mg IV (n = 35)
Excluded (n = 2):
– conversion to general anesthesia, 2 
Included in the primary analysis
n = 28
Excluded (n = 93):
– did not meet inclusion criteria, 51
– general anesthesia, 28
– insulin-dependant diabetes mellitus, 3
– glucocorticoid treatment, 3
– planned saphenous nerve block, 2
– CAVE prednisolone, 1
– other reasons, 5
– declined to paricipate, 0
Allocated to placebo (n = 35)
Excluded (n = 7):
– conversion to general anesthesia, 5 
– postoperative saphenous nerve block, 1
– postoperative flexion restrictions, 1 
Enrollment
Allocation
Included in the primary analysis
n = 33
Analysis
CONSORT flow diagram for screening, inclusion, and exclusion of trial participants.
spinal local anesthetic dose, propofol seda-
tion, duration of surgery, and fluid administra-
tion (Table 2). No patient received blood com-
ponents during or after surgery.
Outcomes
Results from the functional outcomes are listed 
in Table 3. For the primary outcome, we found 
similar loss of quadriceps muscle strength 
between the 2 groups. These results correspond 
to a relative reduction in quadriceps muscle 
strength of 89% in group MP and 88% in 
group C. We found similar knee circumference 
between the 2 groups. The increase in knee cir-
cumference was 8% in group MP and 9% in 
group C, respectively. Both groups showed a 
similar reduced functional performance using 
TUG testing comparing preoperative and post-
operative measures. 
Pre- and postoperative pain scores (VAS) 
were similar in the 2 groups during knee-
extension testing and TUG test.
CRP levels were statistically significantly 
reduced at 24 hours postoperatively in group 
MP compared with group C; median 33 mg/L 
Table 1. Baseline characteristics by allocation group. Values for 
continuous variables are mean (range) and number for categorical 
variables
Variables Group MP (n = 33) Group C (n = 28)
Age 65 (55–79) 69 (56–80)
Sex (F/M) 20/13 13/15
BMI 32 (21–48) 30 (22–43)
ASA, n (%)  
 I 10 (30) 4 (14)
 II 23 (70) 21 (75)
 III – 3 (11)
Side of surgery (L/R) 19/14 17/11
Oxford Knee Score 36 (23–49) a 34 (19–50)
Range of motion 106 (75–134) 108 (64–131)
Preoperative VAS score 4.3 (0–61) 1.9 (0–32)
a n = 31.
VAS: visual analog scale
D
ow
nl
oa
de
d 
by
 [C
op
en
ha
ge
n U
niv
ers
ity
 L
ibr
ary
] a
t 0
4:5
8 2
6 O
cto
be
r 2
01
7 
Acta Orthopaedica 2017; 88 (5): 543–549 547
Discussion
Our hypothesis was that administration of a single preopera-
tive intravenous dose of MP 125 mg with the associated reduc-
tion of the inflammatory response (Lunn et al. 2011) would 
reduce the early postoperative loss of knee-extension strength 
6–12 months postoperatively (Mizner et al. 2005a); limited 
quadriceps function in general may also be a risk factor for 
falling (de Zwart et al. 2015). In addition, loss of quadriceps 
function is important for postoperative rehabilitation, again 
arguing for evaluation of the pathogenesis. The mechanisms 
for the pronounced reduction in knee-extension strength after 
Table 2. Intraoperative characteristics. Values are mean (range)
 Group MP Group C
Variables  (n = 33) (n = 28) p-value a
Duration of surgery (min) 57 (41–110) 60 (39–121) 0.5
Spinal bupivacaine dose (mg) 11.7 (10–14) 11.3 (9.5–12.5) 0.1
Intraoperative propofol sedation (mg) 215 (0–780) 209 (0–900) 0.9
Crystalloids (L) 1.02 (0.55–1.50) 1.01 (0.65–2.00) 0.9
HES (hydroxyethyl starch) 0 0 –
Packed erythrocytes 0 0 –
Blood loss (mL) 117 (25–750) 126 (0–300) 0.8
a independent-sample t-test (MP versus C)
Table 3. Primary and secondary study outcomes
 Group MP (n = 33) Group C (n = 28) p-value a
Knee-extension strength (Nm/kg body weight), mean (range)  
 Baseline 1.15 (0.33–2.0) 1.17 (0.33–1.9) 
 Discharge 0.10 (0.01–0.28) 0.14 (0.01–0.66) 
 Mean change b 1.04 (0.22–1.9) 1.02 (0.22–1.6) 0.8
 Mean change in % b –89 –88 
Pain during knee-extension strength test ,VAS (mm), median (IQR)
 Baseline 0 (0–13) 1 (0–16) 
 Discharge 30 (11–54) 26 (14–51) 
 Mean change b 21 (10–47) 23 (8–42) 0.7
Knee circumference (cm), mean (range) 
 Baseline) 45 (36–57) 43 (36–50) 
 Discharge 48 (41–62) 47 (41–54) 
 Mean change b 3.6 (–1.5 to 6.5) 3.8 (0.8–7.2) 0.7
 Mean change in % b 8 9 
TUG test (s), mean (range)  
 Baseline 8.5 (5.0–13) c 8.1 (5.0–11) d 
 Discharge 24 (9.9–49) c 25 (5.6–63) d 
 Mean change b 16 (2.9–40) c 17 (0.6–53) d 0.8
 Mean change in % b 183 196 
Pain during TUG test, VAS (mm), median (IQR)  
 Baseline 4 (0–13) c 4 (0–21) d 
 Discharge 6 (0–29) c 10 (6–29) d 
 Mean change b 0 (–7 to 29) c 8 (1–14) d 0.1
CRP (mg/L), median (IQR)   
 Baseline 2 (1–6) 2 (1–7) 0.7
 2 h postoperatively 2 (1–6) 2 (1–6) 0.9
 6 h postoperatively 2 (2–6) 3 (1–7) 0.7
 24 h postoperatively 33 (21–50) 72 (57–92) < 0.001
 48 h postoperatively 83 (56–125) 192 (147–258) < 0.001
Rescue morphine equivalents (mg), median (IQR) 
 baseline to 48 h postoperatively 70 (51–84) c 75 (55–94) 0.5
Nm = Newton meter; IQR = interquartile range
a independent-sample t-test or Mann–Whitney U-test (MP versus C)
b from baseline to discharge
c n = 32
d n = 27
at discharge after TKA. However, this was not the 
case as both groups experienced the well-known 
large decrease in knee-extension strength (group 
MP –89% versus group C –88%) (Holm et al. 
2010, Mizner et al. 2005b). 
Also, we found similar changes in knee circum-
ference between the 2 groups consistent with the 
findings in a study with a similar setup (Lunn et 
al. 2011). However, our results do not match the 
findings in a randomized controlled trial (RCT) 
on unicompartmental knee replacement—a pro-
cedure causing a substantially smaller surgi-
cal trauma, where Rytter et al. (2017) found a 
decrease in knee swelling in the MP group on 
the first postoperative day compared with base-
line. The different findings might be related to the 
amount of hemarthrosis postoperatively due to 
different levels of trauma. Theoretically, the use 
of drains might reduce the intra-articular swelling 
(and thereby knee-extension strength), but drains 
have not been shown to be beneficial in TKA 
(Parker et al. 2004, Husted et al. 2014). 
We examined knee swelling from baseline to 48 
hours postoperatively where the possible positive 
impact of MP may be diminished (Harsten et al. 
2015), as the half-life of MP is only 18–26 hours. 
Overall, the specific role of intra-articular fluid 
accumulation on knee-extension strength may be 
important, but not known after TKA.
We also found that MP did not improve the 
TUG test, probably reflecting the similar loss of 
knee-extension strength in the 2 groups.
Finally, there was no effect of MP on pain during 
the functional tests 48 hours postoperatively, 
which is not unexpected, since the analgesic effect 
of MP lasts for only about 32 hours (Lunn et al. 
2011). Moreover, the 2 groups had similar rescue 
analgesic consumption within the first 48 hours 
after surgery. A difference could perhaps be found 
looking at the opioid consumption in the first 24 
hours postoperatively (Lunn et al. 2011), but this 
was not an outcome in this study. 
Early mobilization is crucial for gaining the 
maximum benefits from TKA (Labraca et al. 
2011), and is considered a cornerstone in the fast-
track setup improving functional performance. 
Preoperative quadriceps strength has been found 
to be a strong predictor of functional performance 
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TKA are probably multi-fold and include an inhibitory arth-
rogenic reflex mechanism (Rice and McNair 2010), pain, 
and swelling (Holm et al. 2010). The arthrogenic inhibitory 
reflex mechanism may include peripheral mechanisms from 
the joint, but also modifying mechanisms at a higher central 
nervous system level where the neuro-inflammatory response 
to injury may contribute. A previous study showed the pres-
ence of inflammatory markers in the cerebrospinal fluid after 
surgery possibly causing an alteration in central signaling 
(Buvanendran et al. 2006) but a study by Rice et al. (2014) 
found no evidence for a central neurological effect on quadri-
ceps inhibition, suggesting a more local effect. 
It has also been discussed whether the early loss of knee-
extension strength is related to use of intra-operative tourni-
quet, but no support for this hypothesis was demonstrated in 
a recent RCT (Harsten et al. 2015) and a tourniquet was not 
used in our study. Other surgical approaches might reduce 
inflammation such as minimal invasive surgery, but have not 
been studied in detail. 
A previous study in bilateral TKA found a sustained sup-
pression of the inflammatory marker interleukin-6 (IL-6) by 
administering three 100 mg doses of hydrocortisone over 24 
hours perioperatively (Jules-Elysee et al. 2012), while the 
same investigators showed that fewer doses of glucocorticoid 
were unable to suppress IL-6 in a durable fashion (Jules-
Elysee et al. 2011). Thus, despite our negative findings, fur-
ther procedure-specific dose–response studies and potential 
second dosing of glucocorticoid to prolong analgesia (Backes 
et al. 2013) would be of interest. 
The strengths of our trial include the high degree of stan-
dardized anesthetic, surgical, and multimodal analgesic 
regime. All patients received spinal anesthesia using bupiva-
caine only, thus avoiding intrathecal opioids. The same surgi-
cal incision technique was used and local infiltration analge-
sia was administered in all patients. Furthermore, the patients 
received similar standardized training by physiotherapists in 
the ward. Finally, the use of only 2 data collectors may have 
minimized the risk of performance bias. Limitations include 
a short follow-up period, and lack of power to evaluate pain 
scores and opioid consumption. Moreover, there are no pre-
vious studies to support the power calculation when using 
glucocorticoids. The minimal clinically important difference 
(MCID) is not known for knee-extension strength, but would 
probably be estimated to ~15% (15% reduced loss in knee-
extension strength in the intervention group compared with 
the placebo group). This difference (with equal mean and SD) 
would call for a much bigger study population than included 
in our study. So before setting up a bigger and potentially 
conclusive RCT than the present study, we decided to do a 
detailed physiological and exploratory RCT. We therefore 
defined a greater effect size than MCID to determine the ten-
tative effect.
In summary, the well-described pronounced early (48 h) 
reduction in knee-extension strength after TKA was not modi-
fied by using a single high-dose of MP, although the systemic 
inflammatory response was reduced. Furthermore, MP did not 
improve functional performance in terms of TUG, knee cir-
cumference, pain scores during testing and opioid consump-
tion. Further studies are required to identify the pathogenic 
mechanisms to loss of knee-extension strength after TKA in 
order to enhance early postoperative recovery.
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